Jiangsu Nhwa Pharmaceutical Third Quarter 2024 Earnings: Misses Expectations
Jiangsu Nhwa Pharmaceutical (SZSE:002262) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥1.38b (up 10% from 3Q 2023).
- Net income: CN¥391.2m (up 15% from 3Q 2023).
- Profit margin: 28% (up from 27% in 3Q 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.39 (up from CN¥0.34 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Jiangsu Nhwa Pharmaceutical Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 4.9%.
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are down 1.9% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Jiangsu Nhwa Pharmaceutical's balance sheet health.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:002262
Jiangsu Nhwa Pharmaceutical
Engages in research and development, production, marketing, and services related to central nervous system drugs in China and internationally.
Flawless balance sheet established dividend payer.
